Zaninelli, S.; Panna, S.; Tettamanti, S.; Melita, G.; Doni, A.; D’Autilia, F.; Valgardsdottir, R.; Gotti, E.; Rambaldi, A.; Golay, J.;
et al. Functional Activity of Cytokine-Induced Killer Cells Enhanced by CAR-CD19 Modification or by Soluble Bispecific Antibody Blinatumomab. Antibodies 2024, 13, 71.
https://doi.org/10.3390/antib13030071
AMA Style
Zaninelli S, Panna S, Tettamanti S, Melita G, Doni A, D’Autilia F, Valgardsdottir R, Gotti E, Rambaldi A, Golay J,
et al. Functional Activity of Cytokine-Induced Killer Cells Enhanced by CAR-CD19 Modification or by Soluble Bispecific Antibody Blinatumomab. Antibodies. 2024; 13(3):71.
https://doi.org/10.3390/antib13030071
Chicago/Turabian Style
Zaninelli, Silvia, Silvia Panna, Sarah Tettamanti, Giusi Melita, Andrea Doni, Francesca D’Autilia, Rut Valgardsdottir, Elisa Gotti, Alessandro Rambaldi, Josée Golay,
and et al. 2024. "Functional Activity of Cytokine-Induced Killer Cells Enhanced by CAR-CD19 Modification or by Soluble Bispecific Antibody Blinatumomab" Antibodies 13, no. 3: 71.
https://doi.org/10.3390/antib13030071
APA Style
Zaninelli, S., Panna, S., Tettamanti, S., Melita, G., Doni, A., D’Autilia, F., Valgardsdottir, R., Gotti, E., Rambaldi, A., Golay, J., & Introna, M.
(2024). Functional Activity of Cytokine-Induced Killer Cells Enhanced by CAR-CD19 Modification or by Soluble Bispecific Antibody Blinatumomab. Antibodies, 13(3), 71.
https://doi.org/10.3390/antib13030071
